(Q57904816)

English

Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance

No description defined

In more languages

Statements

scholarly article

0 references

Significant differences of lymphocytes isolated from ascites of patients with ovarian cancer compared to blood and tumor lymphocytes. Association of CD3+CD56+ cells with platinum resistance (English)

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

George Papatheodoridis

object named as

G. Papatheodoridis

11

0 references

Athanasios Dimopoulos

15

object named as

M.A. Dimopoulos

0 references

author name string

A. Bamias

1

0 references

M.L. Tsiatas

2

0 references

E. Kafantari

3

0 references

C. Liakou

4

0 references

A. Rodolakis

5

0 references

Z. Voulgaris

6

0 references

G. Vlahos

7

0 references

T. Papageorgiou

8

0 references

O. Tsitsilonis

9

0 references

C. Bamia

10

0 references

Ek. Politi

12

0 references

A. Archimandritis

13

0 references

A. Antsaklis

14

0 references

language of work or name

0 references

publication date

July 2007

0 references

Gynecologic Oncology

0 references

106

0 references

75-81

0 references

1

0 references

Cancer statistics, 2003.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Ovarian cancer: epidemiology, biology, and prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Prognostic Value of Tumor-Infiltrating CD4+ T-Cell Subpopulations in Head and Neck Cancers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Second-line treatment of ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Lymphocytes isolated from the peritoneal fluid of women with advanced ovarian carcinoma differ significantly from autologous peripheral blood lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Phenotypic and functional analysis of tumor-infiltrating lymphocytes compared with tumor-associated lymphocytes from ascitic fluid and peripheral blood lymphocytes in patients with advanced ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Cytokine-induced Killer Cells: NK-like T Cells with Cytotolytic Specificity against Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Leveraging the activity of tumor vaccines with cytotoxic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Immune rejection of a large sarcoma following cyclophosphamide and IL-12 treatment requires both NK and NK T cells and is associated with the induction of a novel NK T cell population

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2007.02.029

7 January 2021

Identifiers

10.1016/J.YGYNO.2007.02.029

0 references

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q57904816&oldid=1783658319"